May Modulate Inflammatory Responses Explored for its potential to help regulate inflammation associated with tissue injury and repair
Tirzepatide: Positioned as a dual GIP and GLP-1 receptor agonist, Tirzepatide offers a novel approach to diabetes management
Clinically observed reductions in lean mass during medically induced weight loss [40] are therefore consistent with a substrate-sensitive vulnerability affecting skeletal muscle maintenance
Dosing 1 capsule 1-2 times daily on an empty stomach or as directed
Potential side effects may include injection-site redness, swelling, bruising, itching, tenderness, small lumps, headache, fatigue, nausea, appetite changes, abdominal discomfort, stool changes, dizziness, altered sleep, mood changes, or feeling off. Allergic or immune reactions are also possible, and the FDA has specifically raised concerns about immunogenicity and peptide-related impurities in compounded BPC-157